Drug Profile


Alternative Names: CD123 x CD3; MGD 006; MGD006/S80880; S 80880

Latest Information Update: 14 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MacroGenics
  • Developer MacroGenics; Servier
  • Class Antineoplastics; Bispecific antibodies; Monoclonal antibodies
  • Mechanism of Action CD3 antigen inhibitors; Immunomodulators; Interleukin-3-receptor-alpha-subunit-antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute myeloid leukaemia
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Acute myeloid leukaemia; Myelodysplastic syndromes

Most Recent Events

  • 11 Sep 2017 Interim safety and efficacy data from a phase I trial in Acute myeloid leukaemia and Myelodysplastic syndromes presented at the Annual Congress of European Society for Medical Oncology (ESMO-2017)
  • 05 Jun 2017 Phase-I clinical trials in Acute myeloid leukaemia (Recurrent, Second-line therapy or greater, Treatment-resistant) in Germany, Netherlands (Parenteral), before June 2017
  • 05 Jun 2017 Phase-I clinical trials in Myelodysplastic syndromes (Second-line therapy or greater) in Netherlands, Germany (Parenteral), before June 2017
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top